OCTOBER 2-4, 2018
Quebec City Convention Centre, Canada
Research Associate at INSERM UMR1220-IRSD (Digestive Health Research Institute), Team 2
“Microbial Control of PathoPhysiology”
Dr. Matteo SERINO, BSc, PhD, is a Research Associate at INSERM UMR1220-IRSD (Digestive Health Research Institute), Team 2. Dr SERINO has an extensive experience in metabolic diseases and gut microbiota dysbiosis in both human cohorts and animal models. Recently, he started to study a new triad among dysbiosis, metabolic diseases and enterobacteria infections. He has been recently awarded the French Prize for PhD Student Tutorial and Research (P.E.D.R.).
Microbial Control of PathoPhysiology
The microbial control of host pathophysiology has now been acquired as a common trait in both humans and animals. In fact, gut bacteria have functions going widely beyond a mere implication in digestion. Moreover, both structural and functional alterations of gut microbiota, which define the so-named dysbiosis, are recognised as key co-etiologic factors for multiple pathologies, notably metabolic diseases such as type 2 diabetes and obesity. However, a healthy gut and a mature immune system are key factors to face the metabolic consequences of gut microbiota dysbiosis. Among the plethora of molecules sustaining the bidirectional relationship between gut microbiota and the host, microRNAs appear to play an important role. Recently, we described a novel metabolic triad among hepatic expression of microRNAs, liver triglycerides accumulation and specific taxa of the gut microbiota. Of note, a diet-induced gut microbiota dysbiosis can promote enterobacteria colonisation of the gut epithelium. Importantly, some strains of E. coli enterobacteria can secrete
genotoxins capable of targeting DNA and thus altering its stability. This evidence is directly linked with the tumorigenic activity described for colibactin, a genotoxin produced by enterobacteria and shown to promote cellular senescence. The bacterial genotoxic activity also displays a role in modulating glucose homeostasis and has a strong impact on gut microbiota remodelling. In addition, other non-genotoxic enterobacteria display a capacity to modulate glucose homeostasis and systemic inflammation according to the obese/diabetic status of the host. Thus, a change in the enterobiota represents a novel parameter within the translation of gut microbiota dysbiosis into
PARTENAIRES DE RÉALISATION 2018
BÉNÉFIQ IS …
The international rendezvous on health ingredients that will be held from October 2 to 4, 2018, at the Quebec City Convention Centre in Canada. Anchored in Quebec City’s reputation for excellence in food and health, BENEFIQ is a must-attend event sparking synergy among scientists and industry professionals from this rapidly evolving sector.
An initiative of the Institute of Nutrition and Functional Foods (INAF)